Jesse Crawford

Jesse Crawford, an investor and AFib patient, expressed strong belief in Pulse Biosciences' technology and inquired about Co-Chair Bob Duggan's strategy for partnerships, particularly regarding funding and market expansion.

Answer

Co-Chair and CEO Paul LaViolette acknowledged Jesse's personal experience and vision for AFib therapy, emphasizing the potential for nsPFA to become a first-line, definitive treatment. Co-Chair Bob Duggan elaborated on the challenges of a novel technology, the importance of a label for reimbursement, and the disciplined approach to Vibrance's market development, expecting a label in 4-8 quarters. He mentioned that additional funding would be required, potentially through partnerships, distribution, or other forms, while noting the company's current liquidity and the upcoming readouts for the Vibrance trial by mid-year.

Jesse Crawford, an investor and AFib patient, expressed strong belief in Pulse Biosciences' technology and asked Co-Chair Bob Duggan about the company's strategy for partnerships.

Answer

Co-Chair Bob Duggan discussed the challenges of commercializing a novel technology like nanopulse, emphasizing the importance of top-quality professionals and the need for an FDA label to secure reimbursement. He noted that reimbursement for Vibrance is expected in 4-8 quarters, and the company is deliberately avoiding rushing without it. Mr. Duggan expressed high optimism for CE Mark approval for the catheter and clamp in 2027, citing strong outcomes. He mentioned that additional funding would be required and could come through partnerships or distribution, highlighting the company's current liquidity and careful financial management.